Rising home prices and conservative borrowing have today's homeowners sitting on a record amount of potential cash. Today's mortgage holders saw their home equity increase by...Real Estateread more
Stocks have been grinding sideways, but technical analysts say once they breakout, the move to the upside could be powerful.Market Insiderread more
The fresh round of cuts is on top of an estimated 4,500 temporary layoffs GM and its suppliers handed out to employees as of Friday.Autosread more
Here are the most important things to know about Tuesday before you hit the door including earnings from Nike and likely updates on Trump's trade deals.Marketsread more
The Mac Pro is the only major Apple computer to be assembled in the United States. Most of Apple's products, including the iPhone, are assembled in China and are facing tariff...Technologyread more
Stocks were barely changed. American Express gained, but Netflix was a notable laggard.Marketsread more
Think about the last TV show you recommended to a friend, or the last one that was recommended to you. Odds are, it was from a premium service like HBO, Netflix or Amazon.Entertainmentread more
SpaceX is deep into development of its Starship rocket, with recent updates from CEO Elon Musk showing the first one under construction.Investing in Spaceread more
The new wireless earbuds, codenamed "Puget," are expected to come with an accelerometer and be able to monitor things like the distance run, calories burned, and pace of...Technologyread more
Greta Thunberg, a 16-year-old Swedish environmental activist, delivered a powerful message at the United Nations Climate Action Summit on Monday.Environmentread more
SoftBank wants to push Neumann out of the CEO role ahead of the IPO.Technologyread more
Enzymes producer firm Novozymes presented lower-than-expected earnings on Wednesday on what its CEO considered "weak sales."
Its earnings before interest and tax stood at 973 million Danish crowns ($142 million) in the third quarter of this year. This is lower than the 1.03 billion Danish crowns that a Reuters poll had forecast.
"It's, of course, weak sales in the third quarter," Peder Holk Nielsen, CEO of Novozymes, told CNBC on Wednesday.
The company's shares took a hammering in early trade Wednesday down 11.5 percent.
"It's mainly due to bioenergy in the U.S. and the situation keeps deteriorating as our customers are living through a very difficult time," Nielsen added.
The Danish firm lowered once again its full-year growth sales expectations to a range between 0 and 1 percent, from a 1 and 3 percent gap. In August, the Danish firm lowered its sales guidance for 2016 from between 3-5 percent and 2-4 percent.
Novozymes has been struggling to cope with the consequences of low oil and crop prices.
However, the company's CEO guaranteed that the situation would not be getting worse.
"We think we are seeing the bottom of it. It's not getting any worse, but we were hoping for a bit of tailwind from our innovation in the third quarter," Nielsen said.
Last month, Novozymes acquired the German-based Organobalance a microbial research, for an undisclosed amount.